Table 2.
Outcomes data and NOS score of included publications.
| Author | Year | Type of study | Outcomes | OS HR (95% CI) | PFS HR (95% CI) | NOS score |
|---|---|---|---|---|---|---|
| Afzal | 2019 | Retrospective | OS and PFS | 1.01 (0.4-2) | 0.3 (0.1-0.7) | 6 |
| Araujo | 2021 | Retrospective | OS, PFS | 1.73 (1.23-2.44) | 2.36 (1.67-3.34) | 7 |
| Baeck | 2021 | Retrospective | OS | 1.64 (1.25-2.17) | NA | 8 |
| Buti | 2021 | Retrospective | OS and PFS | 1.57 (1.13-2.18) | NA | 6 |
| Castro Balado | 2021 | Retrospective | OS and PFS | 0.4 (0.17-0.93) | 0.98 (0.43-2.21) | 7 |
| Chalabi | 2020 | Retrospective | OS and PFS | 1.45 (1.2-1.75) | 1.3 (1.1-1.53) | 9 |
| Conde-Estevez | 2021 | Retrospective | PFS | NA | 2.91 (0.88-9.65) | 6 |
| Cortellini | 2020 | Retrospective | OS and PFS | 1.26 (1.04-1.52) | 1.26 (1.07-1.48) | 8 |
| Cortellini | 2021 | Retrospective | OS and PFS | 1.49 (1.26-1.77) | 1.32 (1.13-1.54) | 7 |
| Failing | 2016 | Retrospective | OS and PFS | 0.44 (0.17-1.15) | 0.6 (0.34-1.06) | 8 |
| Fukuokaya | 2021 | Retrospective | OS and PFS | 2.02 (1.28 – 3. 18) | 1.7 (1.23-2.35) | 8 |
| Gaucher | 2021 | Retrospective | OS | 0.8 (0.6-1.08) | NA | 7 |
| Giordan | 2021 | Retrospective | OS and PFS | 1.89 (1.29-2.9) | 1.51 (1.11-2.05) | 8 |
| Hakozaki | 2018 | Retrospective | OS and PFS | 1.9 (0.8-4.51) | NA | 6 |
| Homicsko | 2022 | Retrospective | OS and PFS | CheckMate 069: 2 (0.94-4.26) CheckMate 067: 0.9 (0.57-1.42) CheckMate 066: 1.07 (0.67-1.7) |
CheckMate 069: 2.17 (1.1-4.25) CheckMate 067: 1.03 (0.7-1.52) CheckMate 066: 1.13 (0.74-1.17) |
8 |
| Hopkins | 2020 | Retrospective | OS and PFS | 1.52 (1.27-1.83) | 1.38 (1.18-1.62) | 8 |
| Hopkins | 2021 | Retrospective | OS and PFS | 1.53 (1.21-1.95) | 1.34 (1.12-1.61) | 8 |
| Hossain | 2020 | Retrospective | OS and PFS | 1.66 (0.81-3.42) | 1.34 (1.12-1.61) | 6 |
| Husain | 2021 | Retrospective | OS | 1.99 (1.15-3.45) | NA | 7 |
| Iglesias-Santamaria | 2019 | Retrospective | OS and PFS | 0.79 (0.4-1.56) | 0.75 (0.42-1.34) | 8 |
| Jun | 2021 | Retrospective | OS | 1.14 (0.84-1.54) | NA | 7 |
| Kostine | 2021 | Retrospective | OS and PFS | 1.7 (1.4-2.08) | 1.37 (1.12-1.66) | 7 |
| Kulkarni | 2019 | Retrospective | OS and PFS | NSCLC: 1.55 (1 - 2.4) Renal cell carcinoma: 1.01 (0.39 - 2. 62) |
NSCLC: 1.15 (0.79 - 1.66) Renal cell carcinoma: 1.03 (0.53 - 1.97) |
6 |
| Kunimitsu | 2022 | Retrospective | OS and PFS | 0.8 (0.4-1.56) | 1.44 (0.79-2.6) | 8 |
| Miura | 2021 | Retrospective | OS | 1.36 (0.96-1.91) | NA | 8 |
| Mollica | 2021 | Retrospective | OS and PFS | Nivolumab + ipilimumab: 1.12 (0.38 - 3.27) Nivolumab: 0.81 (0.53 - 1.24) |
Nivolumab + ipilimumab: 1.04 (0.49 - 2.2) Nivolumab: 1.05 (0.73 - 1.5) |
8 |
| Nguyen | 2019 | Retrospective | OS and PFS | 1.51 (0.87 - 2.6) | 1.29 (0.8 - 2.07) | 6 |
| Okuyama | 2022 | Retrospective | OS and PFS | 1.78 (1.03-3.07) | 1.72 (1.07-2.77) | 7 |
| Peng | 2022 | Retrospective | OS and PFS | 1.22 (0.8-1.96) | 1.05 (0.76-1.45) | 8 |
| Perez-Ruiz | 2020 | Retrospective | OS | 2.6 (1.6-4.22) | NA | 7 |
| Rassy | 2022 | Retrospective | OS and PFS | 1.24 (0.98-1.58) | 0.89 (0.74-1.08) | 6 |
| Routy | 2017 | Retrospective | OS and PFS | 1.15 (0.87 - 1.53) | 1.12 (0.83 - 1.51) | 6 |
| Ruiz-Banobre | 2021 | Retrospective | OS and PFS | 1.83 (1.11-3.02) | 1.94 (1.22-3.09) | 9 |
| Spakowicz | 2020 | Retrospective | OS | 0.99 (0.85-1.16) | NA | 6 |
| Stein | 2021 | Retrospective | OS | 1.83 (1.2-2.78) | NA | 8 |
| Stokes | 2021 | Retrospective | OS | 0.96 (0.89-1.04) | NA | 7 |
| Svaton | 2020 | Retrospective | OS and PFS | 0.822 (0.487-1.388) | 0.737 (0.485-1.121) | 8 |
| Takada | 2022 | Retrospective | OS and PFS | 2.55 (1.31-4.99) | 4.12 (2.28-7.46) | 7 |
| Tomita | 2022 | Retrospective | OS | 2.47 (1.28-4.74) | NA | 7 |
| Tomizaki | 2022 | Retrospective | OS and PFS | 4.0 (1.22-13.15) | 3.36 (1.17-9.60) | 7 |
| Zaho | 2019 | Retrospective | OS and PFS | 1.47 (0.7-3.06) | 1.1 (0.65-1.85) | 8 |
OS, overall survival; PFS, progression-free survival; HR, hazard ratio; NOS, Newcastle–Ottawa Quality Assessment Scale; CI, confidence interval.